ABT-702

ABT-702 is a potent, selective, non-nucleoside small molecule inhibitor of adenosine kinase (AK) with an IC50 of 1.7 nM. Developed by Abbott Laboratories (now AbbVie), it is orally active and has demonstrated significant analgesic and anti-inflammatory effects in various preclinical animal models, including those for acute, inflammatory, and neuropathic pain. Its therapeutic action is mediated by the inhibition of adenosine kinase, which leads to an increase in endogenous adenosine levels and subsequent activation of adenosine receptors, particularly the A1 receptor, through a non-opioid mechanism. Although it showed promise in preclinical studies, ABT-702 did not advance to clinical trials and is currently utilized primarily as a pharmacological research tool.

Other names

4-amino-5-(3-bromophenyl)-7-(6-morpholinopyridin-3-yl)pyrido[2,3-d]pyrimidine